BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 32377723)

  • 1. Proteomics and functional study reveal marginal zone B and B1 cell specific protein as a candidate marker of multiple myeloma.
    Chanukuppa V; Paul D; Taunk K; Chatterjee T; Sharma S; Shirolkar A; Islam S; Santra MK; Rapole S
    Int J Oncol; 2020 Jul; 57(1):325-337. PubMed ID: 32377723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.
    Yang Q; Li K; Li X; Liu J
    Int J Med Sci; 2020; 17(14):2063-2076. PubMed ID: 32922167
    [No Abstract]   [Full Text] [Related]  

  • 3. Integrated bioinformatics analysis reveals novel key biomarkers and potential candidate small molecule drugs in gastric cancer.
    Wu Q; Zhang B; Wang Z; Hu X; Sun Y; Xu R; Chen X; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Xue Q; Zhou YL
    Pathol Res Pract; 2019 May; 215(5):1038-1048. PubMed ID: 30975489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach.
    Chanukuppa V; Paul D; Taunk K; Chatterjee T; Sharma S; Kumar S; Santra MK; Rapole S
    J Proteomics; 2019 Oct; 209():103504. PubMed ID: 31465861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway.
    Feng Y; Zhang L; Wu J; Khadka B; Fang Z; Gu J; Tang B; Xiao R; Pan G; Liu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):54. PubMed ID: 30728056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma.
    Shen Y; Feng Y; Chen H; Huang L; Wang F; Bai J; Yang Y; Wang J; Zhao W; Jia Y; Peng Y; Lei X; He A
    Life Sci; 2018 Mar; 196():133-142. PubMed ID: 29459023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments.
    Zheng MJ; Li X; Hu YX; Dong H; Gou R; Nie X; Liu Q; Ying-Ying H; Liu JJ; Lin B
    J Cell Physiol; 2019 Jul; 234(7):11023-11036. PubMed ID: 30633343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis.
    Yan H; Zheng G; Qu J; Liu Y; Huang X; Zhang E; Cai Z
    J Cell Physiol; 2019 Dec; 234(12):23785-23797. PubMed ID: 31215027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
    Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
    PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
    Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of multiple myeloma associated markers in bone marrow spicules using a novel immunohistochemical technique.
    Santra M; Shaughnessy JD; Bellamy WT
    Biotech Histochem; 2011 Apr; 86(2):119-23. PubMed ID: 20438295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
    Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
    Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
    Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
    Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of TPD52 and DNAJB1 as two novel bile biomarkers for cholangiocarcinoma by iTRAQ‑based quantitative proteomics analysis.
    Ren H; Luo M; Chen J; Zhou Y; Li X; Zhan Y; Shen D; Chen B
    Oncol Rep; 2019 Dec; 42(6):2622-2634. PubMed ID: 31661142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of crucial aberrantly methylated and differentially expressed genes related to cervical cancer using an integrated bioinformatics analysis.
    Ma X; Liu J; Wang H; Jiang Y; Wan Y; Xia Y; Cheng W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32368784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.
    Zhou Z; Li Y; Hao H; Wang Y; Zhou Z; Wang Z; Chu X
    Cell Transplant; 2019 Dec; 28(1_suppl):76S-86S. PubMed ID: 31822116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.
    Zatula A; Dikic A; Mulder C; Sharma A; Vågbø CB; Sousa MML; Waage A; Slupphaug G
    Oncotarget; 2017 Mar; 8(12):19427-19442. PubMed ID: 28038447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
    Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
    Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of serum proteome alterations in human glioblastoma multiforme.
    Gollapalli K; Ray S; Srivastava R; Renu D; Singh P; Dhali S; Bajpai Dikshit J; Srikanth R; Moiyadi A; Srivastava S
    Proteomics; 2012 Aug; 12(14):2378-90. PubMed ID: 22684992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.
    Schinke C; Qu P; Mehdi SJ; Hoering A; Epstein J; Johnson SK; van Rhee F; Zangari M; Thanendrarajan S; Barlogie B; Davies FE; Yaccoby S; Morgan GJ
    Clin Cancer Res; 2018 Jun; 24(12):2913-2919. PubMed ID: 29563136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.